New data shows that cabozantinib, a drug already approved in the treatment of clear cell renal cell carcinoma (ccRCC), elicited promising results in patients with less common non-clear…
David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center in Boston, Massachusetts presented results from the KEYNOTE-427 study at the Genitourinary Cancers…
A phase 1b study showed pembrolizumab and axitinib extended both overall survival (OS) and progression-free survival (PFS) in patients with previously untreated mRCC. “The risk of death was…
Historically, high-sensitivity diagnostic testing for many common diseases consisted of sending samples to an offsite laboratory and potentially waiting hours or days before results were attained and shared…
A new technique makes cancerous tumors glow, which in turn makes it easier to fully remove them during surgery. Employing nanotechnology designed to administer small-molecule drugs, physician researchers…
A research team from Brazil evaluated the link between anxiety and depression — nonmotor symptoms of Parkinson’s disease (PD) — and freezing of gait. They found that roughly…
Interim results from the preliminary analysis of the JAVELIN-Renal 101 trial suggest that adding immunotherapy to a targeted agent appears to significantly improve progression-free survival (PFS) when compared with a…
Genetic testing for Parkinson’s risks can be useful to people with and without the disease. It can also help advance research into the complex condition. Although the testing…
